Research and development

Our development pipeline

Veranschaulichung der Projektphasen

Phasen einer klinischen Entwicklung

Weitere Informationen

Biotest’s development projects involve new therapy options in indications with a particularly high medical need. Moreover, the focus is also on further developing already authorised medicines with the aim of opening up other areas of use or making administration easier and more comfortable for the patient. You will find a summary of our current research and development projects here.

By clicking on the name you will obtain further information about the individual projects.

Our development pipeline

Therapeutic Area

All

Haematology

Clinical immunology

Intensive care medicine

Active substance

Indication

Phase

Active substance & Indication

Phase

   
  • pre
  • 1
  • 2
  • 3
  • reg
  • launch
  • lcm
 

IgG Next Generation
BT595

Primary Immune Deficiency (PID)

IgG Next Generation

BT595
Primary Immune Deficiency (PID)

 

IgG Next Generation
BT595

Idiopathic Thrombocytopenic Purpura (ITP)

IgG Next Generation

BT595
Idiopathic Thrombocytopenic Purpura (ITP)

 

CMV Hyperimmunglobulin
(CMVIG)

Prevention of prenatal CMV transmission

CMV Hyperimmunglobulin

(CMVIG)
Prevention of prenatal CMV transmission

 

Fibrinogen
BT524

Congenital fibrinogen deficiency

Fibrinogen

BT524
Congenital fibrinogen deficiency

 

Fibrinogen
BT524

Acquired fibrinogen deficiency

Fibrinogen

BT524
Acquired fibrinogen deficiency

 

Trimodulin
BT588

"Severe" COVID-19

Trimodulin

BT588
"Severe" COVID-19

 

Trimodulin
BT588

Severe community acquired pneumonia

Trimodulin

BT588
Severe community acquired pneumonia

 

Haemophilia A Therapeutic (HAT)

Haemophilia A

Haemophilia A Therapeutic (HAT)

Haemophilia A Therapeutic (HAT)
Haemophilia A